DNA Biomed Solns
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physi… Read more
DNA Biomed Solns - Asset Resilience Ratio
DNA Biomed Solns (DNA) has an Asset Resilience Ratio of 3.82% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2019)
This chart shows how DNA Biomed Solns's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down DNA Biomed Solns's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA2.35 Million | 3.82% |
| Total Liquid Assets | ILA2.35 Million | 3.82% |
Asset Resilience Insights
- Limited Liquidity: DNA Biomed Solns maintains only 3.82% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
DNA Biomed Solns Industry Peers by Asset Resilience Ratio
Compare DNA Biomed Solns's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for DNA Biomed Solns (2011–2019)
The table below shows the annual Asset Resilience Ratio data for DNA Biomed Solns.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 7.62% | ILA2.80 Million | ILA36.73 Million | -3.20pp |
| 2016-12-31 | 10.82% | ILA4.13 Million | ILA38.17 Million | -5.29pp |
| 2013-12-31 | 16.12% | ILA3.33 Million | ILA20.68 Million | +2.62pp |
| 2012-12-31 | 13.50% | ILA2.86 Million | ILA21.20 Million | +7.30pp |
| 2011-12-31 | 6.20% | ILA1.04 Million | ILA16.82 Million | -- |